Avoro Capital Advisors LLC Has $259.42 Million Position in uniQure N.V. $QURE

Avoro Capital Advisors LLC grew its holdings in uniQure N.V. (NASDAQ:QURE) by 22.6% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,444,444 shares of the biotechnology company’s stock after buying an additional 819,444 shares during the quarter. uniQure makes up 3.4% of Avoro Capital Advisors LLC’s portfolio, making the stock its 12th largest position. Avoro Capital Advisors LLC owned 8.10% of uniQure worth $259,422,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Private Trust Co. NA bought a new stake in shares of uniQure during the 3rd quarter valued at $28,000. Jones Financial Companies Lllp raised its position in uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 509 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in uniQure by 358.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after acquiring an additional 5,538 shares in the last quarter. Knott David M Jr acquired a new position in uniQure during the 3rd quarter worth approximately $117,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in uniQure during the 2nd quarter worth approximately $215,000. 78.83% of the stock is owned by institutional investors.

uniQure Trading Down 8.3%

Shares of QURE stock opened at $15.53 on Friday. The company has a quick ratio of 10.43, a current ratio of 10.43 and a debt-to-equity ratio of 0.25. The firm has a market cap of $971.09 million, a P/E ratio of -4.50 and a beta of 0.73. The company has a 50 day moving average of $21.37 and a 200-day moving average of $29.49. uniQure N.V. has a 12-month low of $7.76 and a 12-month high of $71.50.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The business had revenue of $5.57 million during the quarter, compared to analyst estimates of $4.84 million. Sell-side analysts anticipate that uniQure N.V. will post -3.75 earnings per share for the current year.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and maintained a $70 price target on QURE, giving some institutional-support context despite lowered estimates. HC Wainwright Reaffirms “Buy” Rating for uniQure (NASDAQ:QURE)
• Neutral Sentiment: Market/opinion coverage is running — e.g., a Seeking Alpha piece frames uniQure’s situation as complex and worth reading for background, but it does not add new regulatory facts. A Unique Situation For UniQure
• Negative Sentiment: FDA reportedly issued an unprecedented public rebuke alleging uniQure pushed “distorted” or “manipulated” data related to AMT‑130; plaintiffs’ firms are citing that as the basis to expand securities investigations — a major regulatory risk for the company’s lead program and valuation. QURE ALERT: FDA Reportedly Accuses uniQure of Pushing “Distorted” and “Manipulated” Data …
• Negative Sentiment: Multiple law firms have filed or are soliciting plaintiffs in securities class actions (class period: Sept. 24–Oct. 31, 2025) and have set an April 13, 2026 lead‑plaintiff filing deadline — increasing legal and settlement-tail risk. Representative filings/alerts include Kessler Topaz, Pomerantz and Schall. uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz … QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit …
• Negative Sentiment: HC Wainwright materially cut near‑ and long‑term EPS forecasts (Q1–Q4 2026 and FY2026–FY2030), reducing future earnings visibility and implying a slower timeline to commercialization/profitability despite the Buy rating. That revision increases downside risk to current valuation. uniQure (NASDAQ: QURE) analyst/estimate coverage — MarketBeat

Insider Buying and Selling at uniQure

In other news, insider Jeannette Potts sold 3,412 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $30,912.72. Following the completion of the transaction, the insider owned 138,483 shares in the company, valued at $1,254,655.98. This trade represents a 2.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Christian Klemt sold 12,000 shares of uniQure stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $108,720.00. Following the sale, the chief financial officer owned 226,581 shares in the company, valued at $2,052,823.86. This represents a 5.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 81,399 shares of company stock worth $1,527,645 over the last quarter. Company insiders own 4.79% of the company’s stock.

Analyst Upgrades and Downgrades

QURE has been the subject of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of uniQure in a research note on Tuesday. Wells Fargo & Company upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $15.00 to $60.00 in a report on Monday, March 9th. Barclays started coverage on shares of uniQure in a research report on Tuesday, January 27th. They issued an “equal weight” rating and a $31.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of uniQure in a report on Wednesday, January 21st. Finally, Royal Bank Of Canada upgraded shares of uniQure from a “sector perform” rating to an “outperform” rating and upped their price target for the company from $11.00 to $35.00 in a research note on Monday, March 9th. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $43.25.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.